Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania. Show more

Location: 101 Lindenwood Drive, Malvern, PA, 19355, United States | Website: https://www.galeratx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

2.113M

52 Wk Range

$0.02 - $0.14

Previous Close

$0.03

Open

$0.03

Volume

9,946

Day Range

$0.03 - $0.03

Enterprise Value

149.3M

Cash

6.686M

Avg Qtr Burn

-2.398M

Insider Ownership

32.84%

Institutional Own.

9.99%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tilarginine + paclitaxel Details
Cancer, Triple Negative Breast Cancer

Phase 2

Initiation

Phase 1/2

Data readout

Avasopasem + (fulvestrant +CDK4/6i) Details
Cancer, HR+/HER2-Metastatic Breast Cancer

Phase 1/2

Initiation

Rucosopasem Details
Cancer, Non-small cell lung carcinoma

Failed

Discontinued

Rucosopasem Details
Pancreatic cancer, Cancer

Failed

Discontinued

Avasopasem Manganese (GC4419) Details
Infectious disease, COVID-19

Failed

Discontinued

Avasopasem Manganese (GC4419) Details
Head and neck cancer, Cancer

Failed

Discontinued

Avasopasem Manganese (GC4419) Details
Lung cancer, Esophagitis, Non-small cell lung carcinoma

Failed

Discontinued